Technical Analysis for BLUSF - Bellus Health Inc

Grade Last Price % Change Price Change
grade B 2.04 3.46% 0.0683
BLUSF closed up 3.46 percent on Friday, August 16, 2019, on 47 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Down
See historical BLUSF trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
New Uptrend Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Strong but Oversold Other 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup 3.46%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.46%

Older signals for BLUSF ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


BELLUS Health Inc. is a drug development company focused on rare diseases. The business activities of the Company are development of the Company's core technology platform, amyloid inhibitors, which focus on chemical compounds that could have the potential to inhibit the formation, deposition and toxicity of amyloid fibrils, which are the underlying causes of certain diseases. The Company operates in the business segment of development of drugs for health solutions. It is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. Its pipeline of rare disease projects includes KIACTA in Phase III for Amyloid A (AA) amyloidosis; KIACTA for sarcoidosis; clinical stage Shigamab for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS), and a research-stage project for amyloid light-chain (AL) amyloidosis. It is partnered with global private equity firm Auven Therapeutics for the development of KIACTA.
Medical Specialties RTT Branches Of Biology Biology Chemical Compounds Drug Development Rare Diseases Histopathology Protein Folding Amyloidosis Health Solutions Rare Disease Amyloid Certain Diseases Escherichia Coli Proteopathy Sarcoidosis

Is BLUSF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 2.6
52 Week Low 0.49
Average Volume 71,464
200-Day Moving Average 1.2033
50-Day Moving Average 2.0562
20-Day Moving Average 2.2481
10-Day Moving Average 2.1241
Average True Range 0.1271
ADX 38.71
+DI 33.9136
-DI 25.9954
Chandelier Exit (Long, 3 ATRs ) 2.2187
Chandelier Exit (Short, 3 ATRs ) 2.2813
Upper Bollinger Band 2.5931
Lower Bollinger Band 1.9031
Percent B (%b) 0.2
BandWidth 30.6926
MACD Line -0.0296
MACD Signal Line 0.0324
MACD Histogram -0.062
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.2275
Resistance 3 (R3) 2.2464 2.2028 2.1963
Resistance 2 (R2) 2.2028 2.1551 2.1934 2.1858
Resistance 1 (R1) 2.1214 2.1256 2.0996 2.1025 2.1754
Pivot Point 2.0778 2.0778 2.0669 2.0684 2.0778
Support 1 (S1) 1.9964 2.0301 1.9746 1.9775 1.9046
Support 2 (S2) 1.9528 2.0006 1.9434 1.8942
Support 3 (S3) 1.8714 1.9528 1.8838
Support 4 (S4) 1.8525